HCM
DMIIR

Heights Capital Management’s Drugs Made In America Acquisition II Corp Right DMIIR Stock Holding History

Heights Capital Management’s Portfolio DMIIR Stock Details DMIIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.4K Sell
417,513
-11,271
-3% -$964 0.01% 235
2026
Q1 		$34.3K Buy
+428,784
New +$48.7K 0.01% 190

Other funds holding DMIIR

MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
TCM
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return

Heights Capital Management's DMIIR Position: Q2 2026 in Review

Heights Capital Management reduced its Drugs Made In America Acquisition II Corp Right (DMIIR) stake by 2.6% in Q2 2026, selling an estimated $964 and leaving 417,513 shares worth $30.4K. The position accounts for 0.01% of the portfolio, ranked #235.

Heights Capital Management first reported a position in DMIIR in Q1 2026 and has held it in 2 quarters since. The position peaked at $34.3K in Q1 2026. 61 funds tracked by Wall St. Rank hold DMIIR as of Q2 2026.

  • Heights Capital Management held 417,513 shares of Drugs Made In America Acquisition II Corp Right worth $30.4K as of Q2 2026.
  • Heights Capital Management sold 11,271 Drugs Made In America Acquisition II Corp Right shares in Q2 2026, an estimated $964.
  • Drugs Made In America Acquisition II Corp Right made up 0.01% of Heights Capital Management's portfolio in Q2 2026, its #235 holding.
  • Heights Capital Management first reported a position in Drugs Made In America Acquisition II Corp Right in Q1 2026 and has held it in 2 quarters since.
  • Heights Capital Management's Drugs Made In America Acquisition II Corp Right position peaked at $34.3K in Q1 2026.
  • 61 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp Right as of Q2 2026.

Based on Heights Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.